Jeppe Thorlacius-Ussing1,2, Stephanie Nina Kehlet1, Sarah Rank Rønnow1, Morten Asser Karsdal1, Nicholas Willumsen3. 1. Biomarkers & Research, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark. 2. Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, 2200, Copenhagen N, Denmark. 3. Biomarkers & Research, Nordic Bioscience, Herlev Hovedgade 205-207, 2730, Herlev, Denmark. nwi@nordicbio.com.
Abstract
PURPOSE: Elastin is a signature protein of lungs. Increased elastin turnover driven by altered proteolytic activity is an important part of lung tumorigenesis. Elastin-derived fragments have been shown to be pro-tumorigenic, however, little is known regarding the biomarker potential of such elastin fragments. Here, we present an elastin turnover profile by non-invasively quantifying five specific elastin degradation fragments generated by different proteases. METHODS: Elastin fragments were assessed in serum from patients with stage I-IV non-small cell lung cancer (NSCLC) (n = 40) and healthy controls (n = 30) using competitive ELISAs targeting different protease-generated fragments of elastin: ELM12 (generated by matrix metalloproteinase MMP-9 and -12), ELM7 (MMP-7), EL-NE (neutrophil elastase), EL-CG (cathepsin G) and ELP-3 (proteinase 3). RESULTS: ELM12, ELM7, EL-NE and EL-CG were all significantly elevated in NSCLC patients (n = 40) when compared to healthy controls (n = 30) (ELM12, p = 0.0191; ELM7, p < 0.0001; EL-NE, p < 0.0001; EL-CG, p < 0.0001). ELP-3 showed no significant difference between patients and controls (p = 0.8735). All fragments correlated positively (Spearman, r: 0.69-0.81) when compared pairwise, except ELM12 (Spearman, r: 0.042-0.097). In general, all fragments were detectable across all stages of the disease. CONCLUSIONS: Elastin fragments generated by different proteases are elevated in lung cancer patients compared to healthy controls but differ in their presence. This demonstrates non-invasive biomarker potential of elastin fragments in serum from lung cancer patients and suggests that different pathological mechanisms may be responsible for the elastin turnover, warranting further validation in clinical trials.
PURPOSE:Elastin is a signature protein of lungs. Increased elastin turnover driven by altered proteolytic activity is an important part of lung tumorigenesis. Elastin-derived fragments have been shown to be pro-tumorigenic, however, little is known regarding the biomarker potential of such elastin fragments. Here, we present an elastin turnover profile by non-invasively quantifying five specific elastin degradation fragments generated by different proteases. METHODS:Elastin fragments were assessed in serum from patients with stage I-IV non-small cell lung cancer (NSCLC) (n = 40) and healthy controls (n = 30) using competitive ELISAs targeting different protease-generated fragments of elastin: ELM12 (generated by matrix metalloproteinase MMP-9 and -12), ELM7 (MMP-7), EL-NE (neutrophil elastase), EL-CG (cathepsin G) and ELP-3 (proteinase 3). RESULTS: ELM12, ELM7, EL-NE and EL-CG were all significantly elevated in NSCLCpatients (n = 40) when compared to healthy controls (n = 30) (ELM12, p = 0.0191; ELM7, p < 0.0001; EL-NE, p < 0.0001; EL-CG, p < 0.0001). ELP-3 showed no significant difference between patients and controls (p = 0.8735). All fragments correlated positively (Spearman, r: 0.69-0.81) when compared pairwise, except ELM12 (Spearman, r: 0.042-0.097). In general, all fragments were detectable across all stages of the disease. CONCLUSIONS:Elastin fragments generated by different proteases are elevated in lung cancerpatients compared to healthy controls but differ in their presence. This demonstrates non-invasive biomarker potential of elastin fragments in serum from lung cancerpatients and suggests that different pathological mechanisms may be responsible for the elastin turnover, warranting further validation in clinical trials.
Authors: J J Yang; G A Preston; W F Pendergraft; M Segelmark; P Heeringa; S L Hogan; J C Jennette; R J Falk Journal: Am J Pathol Date: 2001-02 Impact factor: 4.307
Authors: M Woenckhaus; L Klein-Hitpass; U Grepmeier; J Merk; M Pfeifer; Pj Wild; M Bettstetter; P Wuensch; H Blaszyk; A Hartmann; F Hofstaedter; W Dietmaier Journal: J Pathol Date: 2006-10 Impact factor: 7.996
Authors: A McGarry Houghton; Jay L Grisolano; Mary L Baumann; Dale K Kobayashi; R Dean Hautamaki; Leslie C Nehring; Lynn A Cornelius; Steven D Shapiro Journal: Cancer Res Date: 2006-06-15 Impact factor: 12.701
Authors: Eeva Kettunen; Sisko Anttila; Jouni K Seppänen; Antti Karjalainen; Henrik Edgren; Irmeli Lindström; Reijo Salovaara; Anna-Maria Nissén; Jarmo Salo; Karin Mattson; Jaakko Hollmén; Sakari Knuutila; Harriet Wikman Journal: Cancer Genet Cytogenet Date: 2004-03